Periodic Reporting for period 1 - BALXPAND (The HepaRG-Bio-Artificial Liver: Feasibility of commercialization and expansion of business plan)

End-stage liver disease patients have insufficient mass of functional liver, due to different causes as intoxication, and liver infections. Within a few weeks, their condition can deteriorate to such extent that only 20%-50% of the patients survive. In the Western world, there...